U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H15HgNO5.Na.HO
Molecular Weight 505.85
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MERSALYL

SMILES

[OH-].[Na+].COC(C[Hg+])CNC(=O)C1=C(OCC([O-])=O)C=CC=C1

InChI

InChIKey=WWKZBHGJCDECFG-UHFFFAOYSA-L
InChI=1S/C13H16NO5.Hg.Na.H2O/c1-9(18-2)7-14-13(17)10-5-3-4-6-11(10)19-8-12(15)16;;;/h3-6,9H,1,7-8H2,2H3,(H,14,17)(H,15,16);;;1H2/q;2*+1;/p-2

HIDE SMILES / InChI
MERSALYL (Mersal) is an organomercury compound, mercurial diuretics that superseded by safer diuretics such as thiazides, and is hardly used anymore. Due to the idiosyncratic nature of mercury toxicity, the risk of severe disease and sudden death are unpredictable and frequently show no warning signs. Mercurial diuretics cause diuresis by reducing the reabsorption sodium in the ascending loop of Henle, thus causing more water being delivered to the distal convoluted tubule. Unfortunately, earlier physicians misconstrued hallmark symptoms of mercury poisoning such as excessive salivation as signs of mercury's efficacy, including up until the early 1960s when the use of mercurial diuretics was halted in medicine.

Originator

Sources: Pharmaceutical Journal, Volume 95, Pages 300-1, Journal, 1915

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Mersal

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
15 mL multiple, intravenous
Dose: 15 mL
Route: intravenous
Route: multiple
Dose: 15 mL
Sources:
unhealthy, 75
n = 1
Health Status: unhealthy
Condition: carcinoma of the stomach
Age Group: 75
Sex: M
Population Size: 1
Sources:
Other AEs: Bladder discomfort, Restlessness...
Other AEs:
Bladder discomfort
Restlessness
Muscle cramps
Dehydration
Sources:
AEs

AEs

AESignificanceDosePopulation
Bladder discomfort
15 mL multiple, intravenous
Dose: 15 mL
Route: intravenous
Route: multiple
Dose: 15 mL
Sources:
unhealthy, 75
n = 1
Health Status: unhealthy
Condition: carcinoma of the stomach
Age Group: 75
Sex: M
Population Size: 1
Sources:
Dehydration
15 mL multiple, intravenous
Dose: 15 mL
Route: intravenous
Route: multiple
Dose: 15 mL
Sources:
unhealthy, 75
n = 1
Health Status: unhealthy
Condition: carcinoma of the stomach
Age Group: 75
Sex: M
Population Size: 1
Sources:
Muscle cramps
15 mL multiple, intravenous
Dose: 15 mL
Route: intravenous
Route: multiple
Dose: 15 mL
Sources:
unhealthy, 75
n = 1
Health Status: unhealthy
Condition: carcinoma of the stomach
Age Group: 75
Sex: M
Population Size: 1
Sources:
Restlessness
15 mL multiple, intravenous
Dose: 15 mL
Route: intravenous
Route: multiple
Dose: 15 mL
Sources:
unhealthy, 75
n = 1
Health Status: unhealthy
Condition: carcinoma of the stomach
Age Group: 75
Sex: M
Population Size: 1
Sources:
PubMed

PubMed

TitleDatePubMed
On the opening of an insensitive cyclosporin A non-specific pore by phenylarsine plus mersalyl.
2007
Patents

Sample Use Guides

mersalyl 2 ml. intramuscularly, over a period of six days
Route of Administration: Intramuscular
In Vitro Use Guide
Renal cortical slices (about 5 x 5 x 0.5 mm) from New Zealand white rabbits, fed a sodium-deficient rabbit Chow for 2 to 3 weeks, were prepared. Two or three slices were incubated at 37’C for two to three periods of 1 hr each, unless otherwise indicated, in 2 ml of medium that was continuously gassed with 100% 02. The composition of the standard incubation medium was (in mM): NaC1, 145; KC1, 5.5; CaCl2, 2.0; MgCl2, 1.0; glucose, 10; N-2-hydroxyethylenepiperazine-N-2-ethanesulfonic acid, 10. The pH was adjusted to 7.0. The Na+-free and Cl--free medium was prepared by substituting Na+ with K+, and Cl- with isethionate (2-hydroxyethanesulfonate), respectively. The Na+-free modified medium did not contain 2 mM CaCl2 but contained 2 mM EGTA. In this Na+-free, high K+ medium, Ca2+ was found to exert a marked inhibitory effect on renin secretion. Therefore, Ca2+ was excluded from the medium to avoid the complication of the inhibitory effect of Ca2+ on renin secretion superimposed on the stimulatory effect of EA. The first 1-hr incubation in the standard medium served as the control. For subsequent periods, slices were incubated in media containing different ionic compositions or with MERSALYL (10mkM-3mM). In parallel, slices were incubated in the standard medium without test reagents as the time control. At the end of each incubation period, medium was collected and renin activity was determined by radioimmunoassay of angiotensin I generated following incubation of an aliquot of collected medium with plasma of 48-hr nephrectomized rabbits.
Name Type Language
MERSALYL
INN   MI   WHO-DD  
INN  
Official Name English
(3-((2-(CARBOXYLATOMETHOXY)BENZOYL-.KAPPA.O)AMINO)-2-METHOXYPROPYL-.KAPPA.C)HYDROXYMERCURATE(1-) SODIUM (1:1)
Common Name English
MERSALYL-THEOPHYLLINE COMPONENT MERSALYL SODIUM
Common Name English
Mersalyl [WHO-DD]
Common Name English
MERSALYL SODIUM [MART.]
Common Name English
N-(.GAMMA.-HYDROXYMERCURI-.BETA.-METHOXYPROPYL)SALICYLAMIDE-O-ACETIC ACID SODIUM SALT
Common Name English
MERSALYL [MI]
Common Name English
MERSALYL SODIUM [ORANGE BOOK]
Common Name English
MERCURAMIDE
Common Name English
MERSALYL SODIUM COMPONENT OF MERSALYL-THEOPHYLLINE
Common Name English
MERCURATE(1-), (3-((2-(CARBOXYLATOMETHOXY)BENZOYL-.KAPPA.O)AMINO)-2-METHOXYPROPYL-.KAPPA.C)HYDROXY-, SODIUM
Common Name English
O-((3-(HYDROXYMERCURI)-2-METHOXYPROPYL)CARBAMOYL)PHENOXYACETIC ACID SODIUM SALT
Common Name English
mersalyl [INN]
Common Name English
MERSALYL SODIUM
MART.   ORANGE BOOK  
Common Name English
SODIUM SALT OF O-((3-HYDROXYMERCURI-2-METHOXYPROPYL)CARBAMOYL)PHENOXYACETIC ACID
Common Name English
SALYRGAN
Brand Name English
SODIUM O-((3-HYDROXYMERCURI-2-METHOXYPROPYL)CARBAMOYL)PHENOXYACETATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C448
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
WHO-VATC QC03BC01
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
WHO-ATC C03BC01
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
Code System Code Type Description
ECHA (EC/EINECS)
207-748-9
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
PRIMARY
FDA UNII
5X1IO031V8
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
PRIMARY
INN
398
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
PRIMARY
DRUG BANK
DB09338
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
PRIMARY
RXCUI
6774
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
PRIMARY RxNorm
DRUG CENTRAL
4657
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201330
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
PRIMARY
WIKIPEDIA
MERSALYL
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
PRIMARY
PUBCHEM
9806195
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
PRIMARY
NCI_THESAURUS
C77560
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
PRIMARY
MERCK INDEX
m7241
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
PRIMARY Merck Index
EVMPD
SUB08779MIG
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
PRIMARY
SMS_ID
100000081713
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
PRIMARY
MESH
D008634
Created by admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
PRIMARY
CAS
492-18-2
Created by admin on Sat Dec 16 16:47:13 GMT 2023 , Edited by admin on Sat Dec 16 16:47:13 GMT 2023
PRIMARY